Cas:1360442-43-8 (R)-2-(3-CHLOROPHENYL)PYRROLIDINE HYDROCHLORIDE manufacturer & supplier

We serve Chemical Name:(R)-2-(3-CHLOROPHENYL)PYRROLIDINE HYDROCHLORIDE CAS:1360442-43-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

(R)-2-(3-CHLOROPHENYL)PYRROLIDINE HYDROCHLORIDE

Chemical Name:(R)-2-(3-CHLOROPHENYL)PYRROLIDINE HYDROCHLORIDE
CAS.NO:1360442-43-8
Synonyms:(R)-2-(3-CHLOROPHENYL)PYRROLIDINE HYDROCHLORIDE
Molecular Formula:C10H13Cl2N
Molecular Weight:218.12292
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:
Exact Mass:
LogP:

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like (R)-2-(3-CHLOROPHENYL)PYRROLIDINE HYDROCHLORIDE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(R)-2-(3-CHLOROPHENYL)PYRROLIDINE HYDROCHLORIDE physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(R)-2-(3-CHLOROPHENYL)PYRROLIDINE HYDROCHLORIDE Use and application,(R)-2-(3-CHLOROPHENYL)PYRROLIDINE HYDROCHLORIDE technical grade,usp/ep/jp grade.


Related News: The expansion will include six 1,000L small molecule reactors, four 1,500L vessels, and isolation equipment providing mid-scale capacity to bridge between early-phase and late-phase production. 6-(Dimethylamino)-2-naphthaldehyde manufacturers The company forecasts that the 70-strong team will grow by around 50% in the next three years to support its clinical and commercial API manufacturing capabilities. methyl 2-amino-2-[4-(trifluoromethyl)phenyl]acetate,hydrochloride suppliers He further explained that getting a new drug to commercial manufacturing is also complex and costly due to the very stringent drug manufacturing regulatory mechanism. 1,2,3-Propanetriyl tri(2H31)hexadecanoate vendor & factory He further explained that getting a new drug to commercial manufacturing is also complex and costly due to the very stringent drug manufacturing regulatory mechanism. ,Altogether, the IPO added $550 million to the family’s collective fortune, which now stands at an estimated $4.8 billion.